Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A
Department of Hemostasis, Hôtel-Dieu, Paris, France.
Fertil Steril. 1997 Sep;68(3):449-53. doi: 10.1016/s0015-0282(97)00220-3.
To assess the effects of oral E2 replacement therapy on various hemostatic parameters and cardiovascular risk factors in healthy, postmenopausal women.
A double-blind, randomized, prospective study comparing the effect of a placebo and of oral micronized E2 (2 mg daily) during a 6-month period. Evaluations were performed before treatment and after 3 and 6 months.
Departments of Gynecology, Hemostasis, and Nutrition, Hôtel-Dieu, Paris, France.
PATIENT(S): Thirty-six healthy women with natural or surgical menopause.
RESULT(S): Compared with placebo, oral E2 replacement therapy resulted in a significant decrease in fibrinogen and apo B and a significant increase in plasminogen.
CONCLUSION(S): Besides the effects on lipoproteins, oral estrogen replacement therapy modifies parameters involved in coagulation and fibrinolysis.
评估口服雌激素（E2）替代疗法对健康绝经后女性各种止血参数和心血管危险因素的影响。
一项双盲、随机、前瞻性研究，比较安慰剂和口服微粒化E2（每日2毫克）在6个月期间的效果。在治疗前以及治疗3个月和6个月后进行评估。
法国巴黎迪厄医院妇产科、止血科和营养科。
36名自然绝经或手术绝经的健康女性。
与安慰剂相比，口服E2替代疗法导致纤维蛋白原和载脂蛋白B显著降低，纤溶酶原显著增加。
除了对脂蛋白的影响外，口服雌激素替代疗法还会改变参与凝血和纤溶的参数。
